sonrotoclax + dexamethasone + daratumumab

Sonrotoclax + dexamethasone + daratumumab is a **combination regimen** of three drugs, evaluated for relapsed/refractory multiple myeloma, especially in patients harboring the t(11;14) genetic abnormality. - **Sonrotoclax (BGB-11417)** is an investigational small molecule inhibitor of B-cell lymphoma 2 (BCL2), designed to induce apoptosis in cancer cells by blocking BCL2, which is often overexpressed in hematologic malignancies and allows cancer cells to evade programmed cell death. Sonrotoclax is more selective and potent than first-generation BCL2 inhibitors and can also inhibit BCL2 mutants linked to resistance[1][5]. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid used widely in multiple myeloma regimens for its immunosuppressive and anti-inflammatory effects that also contribute to anti-tumor activity. - **Daratumumab** is a monoclonal antibody targeting CD38, a surface protein highly expressed on myeloma cells. By inducing immune-mediated cytotoxicity, daratumumab helps in the direct elimination of malignant cells. This triple combination is under clinical investigation (phase 1/2) as part of dose-escalation studies for patients with relapsed/refractory multiple myeloma, aiming to improve efficacy in challenging populations[5].